Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Bruce

Urology Round Rock, TX Medical Doctor

NPI 1356323448 CMS profile 151804

16040 Park Valley Dr Ste 111, Round Rock, TX 78681

Open in the dashboard

General payments

$9,496

275 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Bruce of Round Rock, TX is reported in the CMS Open Payments database as having received $9,496 across 275 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,840 54
2024 General $2,306 51
2023 General $1,220 40
2022 General $953 44
2021 General $612 37
2020 General $281 17
2019 General $2,284 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Bruce
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Robert Bruce were reported at $1,840. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Robert Bruce Urology median Middle half National median
2019 $2,284 $480 $147–$1,201 $163
2020 $281 $246 $87–$645 $114
2021 $612 $358 $111–$1,000 $132
2022 $953 $476 $143–$1,263 $149
2023 $1,220 $560 $168–$1,461 $160
2024 $2,306 $563 $170–$1,464 $164
2025 $1,840 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,799 14 payments
  2. AbbVie, Inc. $1,537 79 payments
  3. Bluewind Medical $1,445 8 payments
  4. Medtronic, Inc. $1,269 15 payments
  5. Coloplast Corp $490 6 payments
  6. Allergan Inc. $410 26 payments
  7. Janssen Biotech, Inc. $345 20 payments
  8. Sumitomo Pharma America, Inc. $304 16 payments
  9. Pfizer Inc. $273 15 payments
  10. Astellas Pharma US Inc $252 15 payments
  11. Other $1,371 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,791 267 payments
  2. Travel and Lodging $2,705 8 payments
Products named General payments · program years 2019–2025
  1. AMS $1,753 12 payments
  2. REVI $1,445 8 payments
  3. INTERSTIM $1,269 15 payments
  4. BOTOX Botox Therapeutic $946 44 payments
  5. BOTOX Hyperhydrosis $620 39 payments
  6. XTANDI $431 25 payments
  7. ERLEADA $320 19 payments
  8. Altis $279 2 payments
  9. XIAFLEX $265 18 payments
  10. LUPRON DEPOT $260 16 payments
  11. Other $2,707 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,126

Median for Urology: 1,053

Drug cost

$539,612

Median for Urology: $101,464

Branded share of claims

53.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 22 $295,053
Myrbetriq Mirabegron Brand 82 $81,274
Orgovyx Relugolix Brand 25 $65,937
Gemtesa Vibegron Brand 62 $56,245
Mirabegron Er Mirabegron Brand 19 $13,700
Estradiol Generic 154 $7,757
Solifenacin Succinate Generic 126 $4,870
Potassium Citrate Er Potassium Citrate Brand 17 $2,282
Fosfomycin Tromethamine Generic 13 $2,274
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 49 $2,178

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 137 billing codes

Paid by Medicare

$285,667

Of which drugs: $49,542

Medicare patients

753

Average age 75

Services billed

15,188

328 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 34%
Diabetes 30%
Cancer 24%
Depression 23%
Chronic kidney disease 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 31 7,600 $36,950
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 25 2,500 $250
Injection, ceftriaxone sodium, per 250 mg J0696 Office 39 200 $68

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $286
$286 — 7,600
ORGOVYX
  • Sumitomo Pharma America, Inc. $97
  • PFIZER INC. $27
$124 25 —
XTANDI
  • Astellas Pharma US Inc $51
  • PFIZER INC. $27
$78 22 —
ERLEADA
  • Janssen Biotech, Inc. $76
$76 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record